(Total Views: 636)
Posted On: 05/10/2025 11:31:09 PM
Post# of 154726
From the last shareholders letter…
“ CytoDyn continues to prioritize the publication of our clinical data. The exciting observation of improved survival in patients with mTNBC treated with leronlimab has naturally prompted us to reframe the focus of our oncology manuscripts. Submission of these oncology manuscripts for peer review is a top publication priority. Additional ongoing publication efforts include:
The manuscript for our CD02 Phase 3 study in patients with multi-drug-resistant HIV was recently published by the Journal of Acquired Immune Deficiency Syndromes and has been posted to our website.
The manuscripts for the CD12 Acute Covid and MASH clinical studies are in final preparation for submission.
A manuscript summarizing the results of treatment with leronlimab on liver fibrosis from SMC is in preparation.
As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be complete shortly.”
FWIW
“ CytoDyn continues to prioritize the publication of our clinical data. The exciting observation of improved survival in patients with mTNBC treated with leronlimab has naturally prompted us to reframe the focus of our oncology manuscripts. Submission of these oncology manuscripts for peer review is a top publication priority. Additional ongoing publication efforts include:
The manuscript for our CD02 Phase 3 study in patients with multi-drug-resistant HIV was recently published by the Journal of Acquired Immune Deficiency Syndromes and has been posted to our website.
The manuscripts for the CD12 Acute Covid and MASH clinical studies are in final preparation for submission.
A manuscript summarizing the results of treatment with leronlimab on liver fibrosis from SMC is in preparation.
As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be complete shortly.”
FWIW
(9)
(0)
